One major challenge in cancer genetics is figuring out which of the millions of protein-coding mutations drive disease. A report appearing in Nature Biotechnology describes a new method that combines experimental and computational approaches to assess the functions of these genetic alterations. The work builds on sequencing tools developed in the Broad Institute labs of KI members Aviv Regev and Jesse Boehm.